First, the TL; DR: I'm trying to build a comprehensive list of databases containing information about Tyrosine Kinase Inhibitors, or TKIs. Public or private Dbases are both OK. I will curate the list over time in response to your replies - Thank you!!
Part 0 - Goal: To gather data types on tyrosine kinase inhibitors (TKIs) (drugs that target [receptor] tyrosine kinases (RTKs)) to treat cancer or other diseases.
Part 1 - Scope & Data of interest:
- PK and PD data. Toxicity reports from Phase I, dose response curves, IC50s, GI50s.
- Aggregated Tyrosine Kinase Inhibition/Specificity panels
- Pharmacogenomic (PG) data (e.g., how does the IC50 of the a TKI change if a given mutation arises?
- QSAR data (weak on this so far)
- Protein homology data (perhaps uniprot or the like integrated with drug response, if that exists?) Would be interested in your suggestions here.
Part 2 - Databases curated to Date:
- The Cancer Therapeutics Response Portal (CTRP) (currently v2.1), the most recent citation for which can be found here.
- PharmacoDB, the citation for which can be found here.
- Genomics of Drug Sensitivity in Cancer (GDSC), the citations for which can be found here.
- Project Achilles, the citations for which can be found here.
- The Cancer Cell Line Encyclopedia (CCLE), the citations for which can be found here.
- The Cancer Target Discovery and Development Network (CTD2), the citations for which can be found here. Update #1 (Thursday August 8th, 2022):
- NIH PubChem, needs no introduction.
- FDA.gov lists of all approved TKIs with attendant information.
- PKIDB, the citation to which is here, which supplements the approved FDA list by curating information from clinical trials. Not sure what the limitations are.
- Kinase MD, a NAR paper from last year (see table 1 of manuscript for content description).
Part 3: Non-redundant Databases, or DB Dependencies, so to speak: These DBs rely not on their own earlier versions as well as also on additional databases. For instance, the documentation page at PharmacoDB v2.1 refers to CCLE (mentioned above) as well as NCI60 (not mentioned above, but subsumed by the above lists...).
Part 4: Content, Strengths and Limitations: Over time, with your help, it would be good to build a list of content, strengths, and weaknesses of each DB.